CARY, N.C.--(BUSINESS WIRE)--Cetero Research, the leading early-phase contract research organization (CRO), today announced the appointment of Troy W. McCall, PhD, as Chief Executive Officer. Jerry Merritt, PharmD, Cetero’s former CEO, has been promoted to Executive Chairman of the Board of Directors and will work closely with Dr. McCall to ensure a smooth transition.
Dr. McCall brings more than 17 years of experience in the pharmaceutical and CRO industries. Prior to joining Cetero, he was CEO of Premier Research Group, an international full-service CRO with more than 1,200 employees operating in 30 countries. During his tenure at Premier Research, he was responsible for global management and strategy, including the successful integration of four acquisitions. Dr. McCall’s additional CRO experience includes senior management positions at PharmData and Advanced Clinical Research Services. Dr. McCall’s drug-development experience includes serving as Vice President of Pharmaceutical Development at Penwest Pharmaceuticals, where he led the efforts for the development and regulatory approval of multiple products as well as serving as co-inventor on four patents. Dr. McCall holds a PhD in Pharmaceutics with a specialization in pharmacokinetics from the University of Tennessee Health Sciences Center and graduated from Christian Brothers University with a BS in Chemistry.
“We went through an exhaustive search to find the very best leader for Cetero’s future. Troy surpassed all of our stringent criteria,” said Dr. Merritt. “He understands our business from the perspective of a pharmaceutical client and also brings extensive CRO experience leading global operations. As we enter into this new decade knowing the pharmaceutical industry needs flexibility and rapid, high-quality data, Troy is precisely the right choice to further advance Cetero’s position as the recognized leader in early-phase and bioanalytical research.”
“I am very excited to be part of the Cetero Research team. Under Jerry’s direction, Cetero has integrated five companies to create a foundation strong in science, experience and quality,” said Dr. McCall. “In 2010 and beyond, we will maintain our unparalleled focus on quality and customer service as we continue our investments in innovative advancements that best serve our clients. Cetero will continue to be a true partner in drug development for the pharmaceutical industry to support our clients with the challenges they face today and in the future.”
About Cetero Research
Cetero Research is an industry leading contract research organization (CRO) in early phase research services. With more than 25 years of experience from its founding companies, Cetero has conducted more than 10,000 clinical pharmacology studies – more than any other CRO. Cetero’s proven track record allows the company to provide flexible and high quality drug development services, and its time-tested systems produce consistent and reliable data Cetero’s clients can trust. Cetero’s clinical research expertise consists of traditional early-stage, healthy-volunteer clinical pharmacology and bioavailability studies, as well as specialty Phase Ia/b trials in patients. Its bioanalytical services support clinical, preclinical drug and biomarker analysis for small and large molecules. In addition, Cetero owns and operates a full-scale central laboratory supporting Phase I-IV clinical trials in North and South America. For more information, visit www.cetero.com, or call 877.7CETERO.
Contact:
Cetero Research April Johnson, 919-468-4214 (Direct) Senior Director, Marketing april.johnson@cetero.com
